Daphne M Moutsoglou1, Stephen C Dreskin. 1. Division of Allergy and Clinical Immunology and Departments of Medicine and Immunology, University of Colorado Denver, Aurora, Colo., USA.
Abstract
BACKGROUND: Anti-peanut immunoglobulin E (anti-Pn IgE) can persist throughout life, suggesting that this condition could be maintained by long-lived antibody-secreting cells (ASCs). To determine the role of long-lived ASCs, peanut-allergic mice underwent prolonged treatment with the proteasome inhibitor, bortezomib (Bz). METHODS: Intravenous Bz was given twice weekly for 21 weeks to peanut-allergic mice. During treatment, serum anti-Pn IgE was measured, and the mice were rechallenged at the end of treatment. Cell populations were measured, and Pn-specific IgG, total IgG, and total IgE ASCs were enumerated in the bone marrow (BM) and spleen (SPL). RESULTS: Prolonged treatment with Bz significantly reduced serum anti-Pn IgE and IgG1 but did not affect symptoms following challenge with Pn, even in mice with undetectable serum anti-Pn IgE. Numbers of CD138+ cells were significantly reduced in the BM but were unaffected in the SPL. Unexpectedly, Bz did not affect numbers of Pn-specific IgG, total IgG, or total IgE ASCs in either the BM or SPL. CONCLUSIONS: Cells that maintain long-lived serum anti-Pn IgE are sensitive to Bz. However, prolonged depletion of serum Pn-specific IgE does not result in a decrease of symptoms following challenge with Pn.
BACKGROUND: Anti-peanut immunoglobulin E (anti-Pn IgE) can persist throughout life, suggesting that this condition could be maintained by long-lived antibody-secreting cells (ASCs). To determine the role of long-lived ASCs, peanut-allergicmice underwent prolonged treatment with the proteasome inhibitor, bortezomib (Bz). METHODS: Intravenous Bz was given twice weekly for 21 weeks to peanut-allergicmice. During treatment, serum anti-Pn IgE was measured, and the mice were rechallenged at the end of treatment. Cell populations were measured, and Pn-specific IgG, total IgG, and total IgE ASCs were enumerated in the bone marrow (BM) and spleen (SPL). RESULTS: Prolonged treatment with Bz significantly reduced serum anti-Pn IgE and IgG1 but did not affect symptoms following challenge with Pn, even in mice with undetectable serum anti-Pn IgE. Numbers of CD138+ cells were significantly reduced in the BM but were unaffected in the SPL. Unexpectedly, Bz did not affect numbers of Pn-specific IgG, total IgG, or total IgE ASCs in either the BM or SPL. CONCLUSIONS: Cells that maintain long-lived serum anti-Pn IgE are sensitive to Bz. However, prolonged depletion of serum Pn-specific IgE does not result in a decrease of symptoms following challenge with Pn.
Authors: T Hideshima; P Richardson; D Chauhan; V J Palombella; P J Elliott; J Adams; K C Anderson Journal: Cancer Res Date: 2001-04-01 Impact factor: 12.701
Authors: Terry H Landowski; Christina J Megli; Kevin D Nullmeyer; Ronald M Lynch; Robert T Dorr Journal: Cancer Res Date: 2005-05-01 Impact factor: 12.701
Authors: Ruud Oerlemans; Niels E Franke; Yehuda G Assaraf; Jacqueline Cloos; Ina van Zantwijk; Celia R Berkers; George L Scheffer; Kabir Debipersad; Katharina Vojtekova; Clara Lemos; Joost W van der Heijden; Bauke Ylstra; Godefridus J Peters; Gertjan L Kaspers; Ben A C Dijkmans; Rik J Scheper; Gerrit Jansen Journal: Blood Date: 2008-06-18 Impact factor: 22.113
Authors: Jin-Shu He; Michael Meyer-Hermann; Deng Xiangying; Lim Yok Zuan; Leigh Ann Jones; Lakshmi Ramakrishna; Victor C de Vries; Jayashree Dolpady; Hoi Aina; Sabrina Joseph; Sriram Narayanan; Sharrada Subramaniam; Manoj Puthia; Glenn Wong; Huizhong Xiong; Michael Poidinger; Joseph F Urban; Juan J Lafaille; Maria A Curotto de Lafaille Journal: J Exp Med Date: 2013-11-11 Impact factor: 14.307
Authors: Kyle J Bednar; Lakeya Hardy; Johanna Smeekens; Dharmendra Raghuwanshi; Shiteng Duan; Mike D Kulis; Matthew S Macauley Journal: J Vis Exp Date: 2018-10-25 Impact factor: 1.355